[밸류업 점검] SK케미칼, 제약사업 외형성장 카드 '텔암클로' 주목

SK Chemicals is accelerating its pharmaceutical division's growth by launching Telamclo, a triple combination drug, directly aligning with its strategic Corporate Value Enhancement Plan. This move signifies a shift toward high-margin therapies in the expanding hypertension market, aiming to diversify revenue beyond existing blockbusters like Joins.